AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lonafarnib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| farnesyl transferase inhibitors | 5414 | 193275-84-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lonafarnib inhibits farnesyltransferase to prevent farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 40 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TTK | 37 | |||
| kinase-selectivity-class | AXL,PDK1 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 20, 2020 | FDA | EIGER BIOPHARMACEUTICALS INC | |
| July 18, 2022 | EMA | EIGERBIO EUROPE LIMITED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX20 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA MoA | N0000182140 | Cytochrome P450 2C19 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
| FDA MoA | N0000190107 | Organic Anion Transporting Polypeptide 1B1 Inhibitors |
| FDA MoA | N0000190108 | Organic Anion Transporting Polypeptide 1B3 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
| FDA EPC | N0000193938 | Farnesyltransferase Inhibitor |
| FDA MoA | N0000193939 | Farnesyltransferase Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:64133 | EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
Related Drugs by ATC class:
A16AX Various alimentary tract and metabolism products 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hutchinson-Gilford syndrome | indication | 238870004 | DOID:3911 |
| Processingdeficient progeroid laminopathies | indication | ||
| Drug induction of cytochrome p450 CYP3A enzyme | contraindication | 423236002 | |
| Drug inhibition of cytochrome p450 CYP3A enzyme | contraindication | 423819001 | |
| Severe hepatic impairment | contraindication | 710067001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 50MG | ZOKINVY | SENTYNL THERAPS INC | N213969 | Nov. 20, 2020 | RX | CAPSULE | ORAL | 7838531 | July 26, 2029 | REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) |
| 75MG | ZOKINVY | SENTYNL THERAPS INC | N213969 | Nov. 20, 2020 | RX | CAPSULE | ORAL | 7838531 | July 26, 2029 | REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 50MG | ZOKINVY | SENTYNL THERAPS INC | N213969 | Nov. 20, 2020 | RX | CAPSULE | ORAL | Nov. 20, 2027 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES |
| 75MG | ZOKINVY | SENTYNL THERAPS INC | N213969 | Nov. 20, 2020 | RX | CAPSULE | ORAL | Nov. 20, 2027 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Protein farnesyltransferase | Enzyme | INHIBITOR | IC50 | 8.72 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| GTPase HRas | Cytosolic other | INHIBITOR | IC50 | 8.72 | IUPHAR | ||||
| GTPase KRas | Enzyme | INHIBITOR | IC50 | 8.28 | IUPHAR | ||||
| GTPase NRas | Enzyme | INHIBITOR | IC50 | 8.55 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D04768 | KEGG_DRUG |
| IOW153004F | UNII |
| C1257385 | UMLSCUI |
| CHEBI:47097 | CHEBI |
| 336 | PDB_CHEM_ID |
| CHEMBL298734 | ChEMBL_ID |
| 148195 | PUBCHEM_CID |
| DB06448 | DRUGBANK_ID |
| 8191 | INN_ID |
| C115354 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8024 | IUPHAR_LIGAND_ID |
| 1137365008 | SNOMEDCT_US |
| 1137617003 | SNOMEDCT_US |
| 4041665 | VANDF |
| 341166 | MMSL |
| 39043 | MMSL |
| d09683 | MMSL |
| 018565 | NDDF |
| 2467553 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zokinvy | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42358-450 | CAPSULE | 50 mg | ORAL | NDA | 28 sections |
| Zokinvy | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42358-475 | CAPSULE | 75 mg | ORAL | NDA | 28 sections |
| Zokinvy | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73079-050 | CAPSULE | 50 mg | ORAL | NDA | 30 sections |
| Zokinvy | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73079-075 | CAPSULE | 75 mg | ORAL | NDA | 30 sections |